PKBO

Peak Bio, Inc. Common Stock
PKBO

Delisted

PKBO was delisted on the 9th of January, 2023.

Back to rankings
 

About: Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing significant unmet needs in the areas of oncology and inflammation.

Healthcare Drug Manufacturers - General

Financial journalist opinion

Neutral
Accesswire
10 months ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Akari Therapeutics, PLC (NASDAQ:AKTX) , relating to its proposed merger with Peak Bio, Inc. Under the terms of the agreement, Akari shareholders are expected to own approximately 52% of the combined company.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
Neutral
GlobeNewsWire
1 year ago
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak's ADC (antibody drug conjugate) platform technology and Akari's PAS-nomacopan Geographic Atrophy (GA) program. Peak's ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari's PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action being developed for GA.
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Neutral
PRNewsWire
1 year ago
Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari
MILWAUKEE , March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari. Click here to learn how to join the https://www.ademilaw.com/case/peak-bio-inc or call Guri Ademi toll-free at 866-264-3995.
Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari
Neutral
GlobeNewsWire
1 year ago
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Neutral
GlobeNewsWire
1 year ago
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office (USPTO). The new patent describes properties of potent heteroaryl-substituted Thailanstatin payloads, proprietary non-cleavable and cleavable linkers, and antibody-drug conjugate (ADC) technology derived from it. Peak Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer.
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
See News Rankings
Charts implemented using Lightweight Charts™